Z-Toremifene - General Information:A first generation selective estrogen receptor modulator (SERM). Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. [PubChem]
Other Brand Names containing Toremifene
Pills Identification Picturescoming soon..
Z-Toremifene - Pharmacology:
Z-Toremifene is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer. Z-Toremifene is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Z-Toremifene inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, Z-Toremifene appears to exert its antitumor effects by binding the estrogen receptors. In cytosols derived from human breast adenocarcinomas, Z-Toremifene competes with estradiol for estrogen receptor protein.
Z-Toremifene for patients
Vaginal bleeding has been reported in patients using Toremifene. Patients should be informed about
this and instructed to contact their physician if such bleeding occurs.
Patients with bone metastases should be informed about the typical signs and symptoms of hypercalcemia
and instructed to contact their physician for further assessment if such signs or symptoms occur.
Drugs that decrease renal calcium excretion, eg, thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. There is a known interaction between antiestrogenic compounds of the triphenylethylene derivative class and coumarin-type anticoagulants (eg, warfarin), leading to an increased prothrombin time. When concomitant use of anticoagulants with FARESTON is necessary, careful monitoring of the prothrombin time is recommended.
Cytochrome P450 3A4 enzyme inducers, such as phenobarbital, phenytoin, and carbamazepine increase the rate of toremifene metabolism, lowering the steady-state concentration in serum. Metabolism of toremifene may be inhibited by drugs known to inhibit the CYP3A4-6 enzymes. Examples of such drugs are ketoconazole and similar antimycotics as well as erythromycin and similar macrolides. This interaction has not been studied and its clinical relevance is uncertain.
FARESTON is contraindicated in patients with known hypersensitivity to the drug.
Indication, Mechanism Of Action, Drug Interactions, Food Interactions, etc..